The current financial score of Fulgent Genetics Inc is 6.70. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 85.39M, representing a year-over-year increase of 4.38%, while its net profit experienced a year-over-year increase of 55.77%.
The current valuation score of Fulgent Genetics Inc is 9.07. Its current P/E ratio is -8.88, which is -185.75% below the recent high of 7.61 and -440.94% above the recent low of -48.02.
The current earnings forecast score of Fulgent Genetics Inc is 6.00. The average price target is 19.00, with a high of 19.00 and a low of 19.00.
The current price momentum score of Fulgent Genetics Inc is 3.61. Currently, the stock price is trading between the resistance level at 22.45 and the support level at 19.56, making it suitable for range-bound swing trading.
The current institutional shareholding score of Fulgent Genetics Inc is 5.00. The latest institutional shareholding proportion is 64.11%, representing a quarter-over-quarter increase of 8.03%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
The current risk assessment score of Fulgent Genetics Inc is 5.42. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.